|
Patent landscape, scope, and claims: |
Executive summary
US Drug Patent 12,453,778 claims a hypoparathyroidism treatment method using a controlled-release PTH(1-34) conjugate of formula (Ia): Z-(L2-L1-D)x where Z is a branched PEG polymer (~40 kDa) and L2-L1 defines a specific linker architecture, with dose adjustment in response to hypocalcemia or hypercalcemia capped at ≤25% per increment and dosing frequency options including q24h, ≤q24h, q48h, and weekly, with subcutaneous administration. The scope is tight around (i) the exact molecular architecture (PEG branch + linker + PTH(1-34)), (ii) the controlled-release regimen tied to calcium homeostasis titration rules, and (iii) specific route and frequency carve-ins.
H1: United States Patent 12,453,778 scope and claims for controlled-release PTH(1-34) hypoparathyroidism
What does claim 1 of US 12,453,778 cover for hypoparathyroidism dosing with controlled-release PTH?
Core claim 1 elements (method of treatment)
Claim 1 is structured as a single, bundled method with these required limitations:
- Indication: treating a patient having hypoparathyroidism.
- Active: administering a pharmaceutical composition comprising a controlled-release PTH compound.
- Formula-defined controlled-release PTH: the compound is of formula (Ia) or a pharmaceutically acceptable salt:
- PEG macrocomponent: Z comprises a branched PEG polymer with molecular weight ~40 kDa.
- Linker architecture: -L2-L1- has a defined chemical structure (as referenced in the claim, with specified attachment sites via amide bonds to nitrogen atoms and asterisk attachment to Z).
- PTH payload definition: -D is PTH(1-34) (SEQ ID NO: 51).
- Stoichiometry parameter: x = 1 (explicitly stated in your claim text: “x is 1.”).
- Dose adjustment rule: the dosage regimen includes dose adjustment in response to hypocalcemia or hypercalcemia in increments of no more than 25%.
- This is a regimen limitation, not a composition limitation, and it is likely the most litigation-relevant “process number” in the claim.
Interpretation that matters for claim scope
- The claim does not just require “PTH(1-34 conjugated to PEG.” It requires the conjugate to match the formula (Ia) architecture and the PEG branching with ~40 kDa**.
- The regimen constraint (“≤25% increments based on hypocalcemia/hypercalcemia”) can narrow claim coverage against dosing that adjusts more aggressively or uses different correction triggers/logic.
How does formula (Ia) likely constrain infringement for US 12,453,778?
Claim 1 ties infringement to whether the accused product uses a controlled-release PTH compound that falls within Z-(L2-L1-D)x with:
- Z: branched PEG, ~40 kDa (not linear PEG, not different molecular weight).
- D: PTH(1-34), SEQ ID NO: 51 (sequence specificity).
- L2-L1 linkage pattern: specific amide bond attachments between the linker and nitrogen atoms, plus defined attachment to Z.
Practically, a product could be clinically “PTH(1-34 PEGylated” and still avoid the claim if its polymer type, size, branching topology, linker chemistry, or substitution pattern differs from formula (Ia).
How do claims 2–6 define dosing frequency and route in US 12,453,778?
Claims 2–6 add regimen and administration specifics that function as narrower embodiments of claim 1.
Claim 2
- Administration no more frequently than once every 24 hours (a maximum dosing frequency cap).
Claim 3
- Administration once every 24 hours (a specific dosing frequency).
Claim 4
- Administration via subcutaneous administration (route limitation).
Claim 5
- Administration once every 48 hours.
Claim 6
- Administration once every week.
Scope implication
- Together, claims 2–6 create a portfolio of covered dosing schedules anchored to claim 1’s dose titration rule and the formula (Ia) conjugate.
- For infringement analysis, clinicians’ actual instructions matter: a product labeling that instructs one frequency may map cleanly to claim language, while off-label dosing may complicate enforcement depending on how the claim is enforced (method-of-use framework).
What is claimed by the moiety “Z comprises a moiety of formula (b)” in claim 7?
Claim 7 narrows claim 1 by specifying that Z comprises a moiety of formula (b). The claim states:
- Dashed line indicates attachment to -L2- or to the remainder of —Z.
- m and p are integers 400 to 500.
Scope implication
- This turns “branched PEG ~40 kDa” into a more granular numerical constraint via PEG chain length parameters (m and p).
- It likely limits coverage to conjugates built with PEG segments in that range, affecting both synthesis specs and analytic characterization.
How does claim 8 further narrow linkage chemistry between PEG and PTH in US 12,453,778?
Claim 8 specifies:
- -L2-L1- is attached by an amide bond to the N-terminal amine functional group of -D (PTH(1-34)).
Scope implication
- This is a specific site-of-attachment limitation. If a competitor uses an alternative conjugation site (different lysine, different engineered terminus chemistry, or a non-amide linkage), it may avoid claim 8 even if it otherwise uses PEG and PTH(1-34).
Patent landscape analysis: how to map US 12,453,778 across composition vs method-of-use risk
Because you provided only the claim text and not the full patent record (publication number, assignee, priority, other claims, specification disclosures, or cited references), a complete landscape cannot be rebuilt from primary data. The analysis below is therefore limited to claim-scope-driven landscape logic: where similar assets usually sit in this technical and legal space and what typical obstacles and design-arounds look like for PEGylated or controlled-release PTH constructs targeting hypoparathyroidism.
Which competitor product attributes are most likely to collide with US 12,453,778?
The highest collision probability products are those that simultaneously satisfy:
- PTH(1-34) controlled-release conjugate (not PTH(1-84), not PTH analogs).
- PEG architecture: branched PEG ~40 kDa with m and p in a 400–500 integer range (if claim 7 is asserted).
- Linker chemistry: amide attachment linking the PEG linker to the N-terminal amine of PTH(1-34) (claim 8).
- Regimen titration: dose adjusted in ≤25% increments based on hypocalcemia/hypercalcemia events (claim 1).
- Route and schedule: subcutaneous, including q24h, q48h, weekly, or “≤q24h” depending on label and instructions (claims 2–6).
Where do design-arounds typically avoid infringement of formula-defined PEG PTH constructs?
Design-arounds are usually concentrated in one of three levers:
(A) Conjugate chemistry: break formula (Ia)
- Alter PEG type (linear vs branched), change polymer size outside ~40 kDa, or shift molecular architecture that changes m/p ranges.
- Use different linker attachment (non-amide link or different conjugation site on PTH).
- Use different substitution pattern such that x ≠ 1 or the structural definition differs from Z-(L2-L1-D)x.
(B) Controlled-release definition through different formulation strategy
- If a competitor uses a controlled-release delivery mechanism (e.g., depot, microspheres, osmotic pumps) while avoiding the specific formula-defined PEG-PTH compound, it may reduce composition collision.
- If the competitor uses the same conjugate but uses a different calcium-titration protocol, it may reduce regimen collision.
(C) Regimen protocol: change the titration increment rule
- The “≤25% increments” rule is an unusually crisp process constraint.
- If an alternative dosing regimen allows adjustment larger than 25% or ties changes to different criteria than hypocalcemia/hypercalcemia, claim 1’s regimen limitation becomes harder to satisfy.
Key infringement vectors by claim: what matters most in litigation
Claim 1: strongest focal point
The most enforceable pinch points are:
- Formula (Ia) constraints (Z branched PEG ~40 kDa; L2-L1 linker; D = PTH(1-34); x = 1).
- Dose adjustment in response to hypocalcemia/hypercalcemia, in increments ≤25%.
In practice, if a competitor product uses a close chemistry but differs on titration increments, claim 1 may be partially avoided. If titration is aligned but the conjugate chemistry differs, composition/formula escape is possible.
Claims 2–6: label-driven vulnerability
These claims track specific schedules (q24h, q48h, weekly) and subcutaneous route. Litigation typically leans on:
- US label instructions and physician-directed administration practices.
- Evidence of actual induced practices, depending on enforcement posture.
Claims 7–8: chemical specificity
These increase specificity and reduce the “cover the general class” effect. They are likely to matter if the challenger’s chemistry is very close:
- Claim 7 pins m and p to 400–500 range.
- Claim 8 pins the amide attachment to the PTH N-terminal amine.
How strong is the patent estate for this concept set?
Given only claim 1 and dependent claims 2–8, the patent appears designed to:
- Claim a specific controlled-release PTH(1-34) PEG conjugate architecture through formula (Ia).
- Lock down route and frequency as additional dependent layers.
- Add numerical PEG segment constraints (m and p) and site-of-attachment constraints (claim 8).
- Include a regimen numeric cap on dose adjustment tied to calcium abnormalities, which can be a decisive differentiator in method-of-use challenges.
This is a relatively narrow, highly engineered claim set: strong against close copycat conjugate structures and close adherence to the dosing protocol, weaker against “different conjugate, different release system, or different titration logic” strategies.
Key Takeaways
- US 12,453,778 claim 1 covers a method for hypoparathyroidism using a controlled-release PTH(1-34) conjugate of formula (Ia) with branched PEG ~40 kDa, linked via a defined L2-L1 amide architecture to PTH’s N-terminal amine (site pinned more explicitly in claim 8).
- The method’s most distinctive regimen element is dose adjustment for hypocalcemia/hypercalcemia capped at ≤25% increments.
- Dependent claims add subcutaneous administration and dosing frequency options (q24h, ≤q24h, q48h, weekly).
- Further narrowing occurs in claim 7 via PEG segment integers m and p set to 400–500, and in claim 8 via amide attachment to PTH(1-34) N-terminus.
- Litigation risk for competitors concentrates where their chemistry matches formula (Ia) and their clinical dosing protocols satisfy the ≤25% titration increments requirement.
FAQs
-
Do claims 2–6 require the same titration rule as claim 1?
Yes. Claims 2–6 depend on claim 1, so the ≤25% hypocalcemia/hypercalcemia adjustment rule remains required.
-
If a product uses PTH(1-34)-PEG but with a different PEG molecular weight than ~40 kDa, does it avoid US 12,453,778?
It may, because claim 1 requires Z to include a branched PEG polymer with molecular weight about 40 kDa, and claim 7 further specifies m and p between 400 and 500.
-
How decisive is the “x is 1” limitation in formula (Ia)?
It can be decisive for infringement if the competitor’s conjugation yields a different effective substitution pattern or stoichiometry than the claimed x = 1.
-
Can a competitor avoid infringement by changing the dose adjustment increments without changing the molecule?
Claim 1’s method limitation ties infringement to dosing where hypocalcemia/hypercalcemia adjustments are made in ≤25% increments, so changing that rule can create a pathway.
-
Is subcutaneous administration mandatory for claim 4 infringement?
For claim 4, yes. But claim 1 alone is broader regarding route unless the specification limits the method; claim 4 is the explicit route-dependent embodiment.
References
- User-provided claim text for US Drug Patent 12,453,778 (claims 1–8).
More… ↓
⤷ Start Trial
|
